Equity Research Associate - Emerging Immunology

Job Title: Equity Research Associate – Emerging Immunology Reports to: Sr. Equity Research Analyst Department: Equity Research Location: New York or Boston Salary Range: $110,000-$150,000 This individual will work closely with senior equity research professionals to develop expertise in emerging immunology, covering companies developing novel therapies in autoimmune disease, inflammation, and related areas. The associate role spans fundamental analysis, scientific diligence, and client-facing research, offering a unique position at the intersection of science and finance. The ideal candidate will possess a strong sense of intellectual curiosity and independent thought, passion for investing as well as the ability to thrive in a fast-moving, deadline driven environment. Primary Duties and Responsibilities: Formulate in-depth investment recommendations based on fundamental analysis, valuation and risk assessment across the emerging immunology landscape Collect and rigorously analyze data related to therapeutics and various diseases, including scientific papers, clinical data, and KOL perspectives Design and execute primary market research, including market surveys and expert interviews, synthesizing findings into differentiated investment insights Build, maintain, and refine financial models, including DCFs, probability adjusted revenue forecasts, and scenario analyses Author research reports, initiation notes, and company updates for distribution to Leerink Partners’ institutional clients and sales force Engage directly with institutional clients and internal stakeholders to communicate investment views and respond to market-driven inquiries Monitor news, data releases, and regulatory updates across the coverage universe, providing timely commentary to clients and the sales force Support senior equity analysts at medical and industry conferences Experience and Qualifications Required: Academic background strongly preferred: MD, PhD, or PharmD Direct exposure to immunology, inflammation, autoimmune disease, or related therapeutic areas is a strong plus Excellent written and verbal communication skills Ability to search, understand and distill complex scientific and medical publications into succinct and actionable insights for biotech investors Familiarity with the biotechnology and pharmaceutical industries including clinical development, regulatory affairs, business development and commercialization Strong quantitative, financial modeling, forecasting and Excel skills Comfort interpreting clinical trial statistics, including statistical powering, trial design strategies (e.g., ITT versus PP), and hazard ratios About Leerink As the leading investment bank to the healthcare and life science industries, we help our clients move healthcare forward. With differentiated sector knowledge, unrivaled expertise, and a complete suite of capital market and advisory solutions, we are the industry’s partner of choice. Leerink Partners is a member of FINRA/SIPC. For more information, please visit: Equal Employment Opportunity Leerink Partners is an equal opportunity employer and is dedicated to expanding its commitments and investments to create a more diverse, equitable and inclusive company culture and innovative ecosystem. We are strongly committed to the values and policy of equal employment opportunity across our employment practices. Actual starting base pay will be determined on skills, experience, and other non-discriminatory factors permitted by law. Total compensation may also include variable incentives, bonuses, benefits, and/or other perks, as outlined in any formal offer made. At Leerink Partners, we share a common desire to achieve the highest level of success for our clients. If you are passionate about healthcare and investing, our team has unmatched access to the necessary resources and support to leverage your talents and expertise into valuable contributions for our clients. Leerink Partners is a leading investment bank providing a complete suite of financial solutions comprising M&A advisory, equity, debt, and derivative capital markets, equity research, and sales and trading capabilities. The firm’s strategic focus on the healthcare industry empowers it to provide unique advice and insights to its clients. The firm is a broker-dealer registered with the United States Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority.